ES2143780T3 - Compuestos que enlazan las quinasas ciclinodependientes. - Google Patents
Compuestos que enlazan las quinasas ciclinodependientes.Info
- Publication number
- ES2143780T3 ES2143780T3 ES96931174T ES96931174T ES2143780T3 ES 2143780 T3 ES2143780 T3 ES 2143780T3 ES 96931174 T ES96931174 T ES 96931174T ES 96931174 T ES96931174 T ES 96931174T ES 2143780 T3 ES2143780 T3 ES 2143780T3
- Authority
- ES
- Spain
- Prior art keywords
- protein
- amino acid
- full length
- acid residues
- substances
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4738—Cell cycle regulated proteins, e.g. cyclin, CDC, INK-CCR
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Biotechnology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Analytical Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
LA PRESENTE INVENCION IDENTIFICA SUSTANCIAS QUE POSEEN LA PROPIEDAD DE UNIRSE A CINASA DEPENDIENTE DE CICLINA (CDK) QUE COMPRENDEN LAS SIGUIENTES: (I) UN PEPTIDO QUE INCLUYE LOS RESIDUOS AMINOACIDOS 84 A 103 DE LA CADENA COMPLETA DE LA PROTEINA P16, O UN DERIVADO O PORCION ACTIVA DE ELLO; O (II) UN MIMETICO FUNCIONAL DEL FRAGMENTO, DE LA PORCION ACTIVA O DEL DERIVADO; LA SUSTANCIA EXCLUYE LA CADENA COMPLETA DE LAS PROTEINAS P16, P15, P18 Y P19. ESAS SUSTANCIAS SON UTILES EN LA SUPRESION DE TUMORES AL INHIBIR LA FOSFORILIZACION DE LA PROTEINA RB. TAMBIEN SE DESCRIBE AQUI LA RESOLUCION DE LOS MOTIVOS AMINOACIDOS RESPONSABLES DE LA UNION A LAS CDK, UN MOTIVO FLD QUE CORRESPONDE A LOS RESIDUOS AMINOACIDOS 90 A 92 DE LA CADENA COMPLETA DE LA PROTEINA P16, Y UN MOTIVO LWL QUE CORRESPONDE A LOS RESIDUOS AMINOACIDOS 94 A 97 DE LA CADENA COMPLETA DE LA PROTEINA P16. LAS SUSTANCIAS AQUI REVELADAS PUEDEN SER USADAS EN EL TRATAMIENTO DE TRASTORNOS HIPERPROLIFERATIVOS Y PARA EFECTUAR SELECCION POR CRIBADO Y DISEÑAR MOLECULAS CON PROPIEDADES SIMILARES.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9519275.3A GB9519275D0 (en) | 1995-09-21 | 1995-09-21 | Substances and their therapeutic use |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2143780T3 true ES2143780T3 (es) | 2000-05-16 |
Family
ID=10781044
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES96931174T Expired - Lifetime ES2143780T3 (es) | 1995-09-21 | 1996-09-23 | Compuestos que enlazan las quinasas ciclinodependientes. |
Country Status (10)
Country | Link |
---|---|
US (2) | US6569833B1 (es) |
EP (1) | EP0851922B1 (es) |
JP (1) | JP4077514B2 (es) |
KR (1) | KR19990045761A (es) |
AT (1) | ATE188254T1 (es) |
AU (1) | AU6996796A (es) |
DE (1) | DE69605934T2 (es) |
ES (1) | ES2143780T3 (es) |
GB (1) | GB9519275D0 (es) |
WO (1) | WO1997011174A1 (es) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9519275D0 (en) | 1995-09-21 | 1995-11-22 | Univ Dundee | Substances and their therapeutic use |
US6495526B2 (en) | 1996-01-23 | 2002-12-17 | Gpc Biotech, Inc. | Inhibitors of cell-cycle progression and uses related thereto |
US6489305B1 (en) | 1998-05-08 | 2002-12-03 | Canji, Inc. | Methods and compositions for the treatment of ocular diseases |
KR19990086091A (ko) * | 1998-05-25 | 1999-12-15 | 성재갑 | 곤충세포를 이용한 가용성 cdk4/p16 복합체의 대량발현 방법 |
KR20000019889A (ko) * | 1998-09-16 | 2000-04-15 | 성재갑 | 곤충세포를 이용한 cdk4/p16 복합체의 제조방법 |
KR20000019888A (ko) * | 1998-09-16 | 2000-04-15 | 성재갑 | 곤충세포를 이용한 cdk4/hc△p16 복합체의 제조방법 및이로부터 cdk4 단백질의 정제방법 |
US6644696B2 (en) | 1998-10-23 | 2003-11-11 | Coinstar, Inc. | Coin-discriminator voucher anti-counterfeiting method and apparatus |
US7166475B2 (en) * | 1999-02-26 | 2007-01-23 | Cyclacel Ltd. | Compositions and methods for monitoring the modification state of a pair of polypeptides |
WO2001011367A1 (fr) * | 1999-08-04 | 2001-02-15 | Medical & Biological Laboratories Co., Ltd. | Methode d'analyse de l'activite enzymatique de phosphorylation du complexe cycline/cdk |
GB0012528D0 (en) * | 2000-05-23 | 2000-07-12 | Univ Palackeho | Triterpenoid derivatives |
GB0030378D0 (en) | 2000-12-13 | 2001-01-24 | Cyclacel Ltd | Compound |
DE60200248T2 (de) * | 2002-08-01 | 2005-01-27 | Mtm Laboratories Ag | Verfahren für Lösung-basierte Diagnose |
AU2004285745A1 (en) * | 2003-10-21 | 2005-05-12 | Cyclacel Limited | Pyrimidin-4-YL-3, 4-thione compounds and their use in therapy |
NZ546983A (en) | 2003-11-24 | 2009-05-31 | Canji Inc | Reduction of dermal scarring |
GB0402653D0 (en) * | 2004-02-06 | 2004-03-10 | Cyclacel Ltd | Compounds |
GB0411791D0 (en) * | 2004-05-26 | 2004-06-30 | Cyclacel Ltd | Compounds |
ATE502931T1 (de) | 2004-08-19 | 2011-04-15 | Dsm Ip Assets Bv | Verfahren zur rektifikation von vitamin e acetat |
ES2403558T3 (es) | 2004-08-27 | 2013-05-20 | Cyclacel Limited | Inhibidores purínicos y pirimidínicos de CDK y su uso para el tratamiento de enfermedades autoinmunitarias |
GB0419416D0 (en) * | 2004-09-01 | 2004-10-06 | Inst Of Ex Botany Ascr | 4-Arylazo-3,5-Diamino-Pyrazole compounds and use thereof |
RU2456297C1 (ru) * | 2010-11-19 | 2012-07-20 | Федеральное государственное учреждение "Российский научный центр рентгенрадиологии" Министерства здравоохранения и социального развития России | Химерный пептид для лечения фиброаденомы молочной железы |
EA201100464A1 (ru) * | 2011-04-06 | 2012-10-30 | Ооо "Метамакс" (Ооо "Метамах") | Фармацевтическая композиция для лечения гиперпролиферативных заболеваний и её применение |
EA028151B1 (ru) | 2013-04-03 | 2017-10-31 | ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "МетаМакс" (ООО "МетаМакс") | Химерный пептид и фармацевтическая композиция для лечения онкологических заболеваний |
CA2986730C (en) * | 2015-05-22 | 2020-04-14 | Expression Pathology, Inc. | Srm/mrm assay for the cyclin-dependent kinase inhibitor 2a (p16) protein |
WO2024036044A1 (en) * | 2022-08-08 | 2024-02-15 | The Johns Hopkins University | Compositions and methods for treating and preventing metabolic disorders |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5362623A (en) | 1991-06-14 | 1994-11-08 | The John Hopkins University | Sequence specific DNA binding by p53 |
FR2662698A1 (fr) | 1990-06-05 | 1991-12-06 | Centre Nat Rech Scient | Nouveaux facteurs de croissance neurotropes comprenant un peptide homeoboite. |
ATE152629T1 (de) | 1990-07-09 | 1997-05-15 | Res Corp Technologies Inc | Diagnose von krebs-metastasen durch das mts-1 gen |
NO312681B1 (no) | 1990-08-24 | 2002-06-17 | Univ California | Fremgangsmåte for fremstilling av en farmasöytisk blanding med suppresiv virkning/aktivitet |
US5331573A (en) * | 1990-12-14 | 1994-07-19 | Balaji Vitukudi N | Method of design of compounds that mimic conformational features of selected peptides |
WO1994009135A1 (en) | 1992-10-16 | 1994-04-28 | Cold Spring Harbor Laboratory | Cyclin complex rearrangement and uses related thereto |
EP1421947A1 (en) | 1992-07-22 | 2004-05-26 | The Trustees Of Princeton University | p53 vaccine |
US6211334B1 (en) | 1992-10-16 | 2001-04-03 | Cold Spring Harbor | Cell-cycle regulatory proteins, and uses related thereto |
US5700657A (en) | 1993-12-13 | 1997-12-23 | Genzyme Corporation | Vectors and vector systems including genes encoding tumor suppressor proteins and producer cells transformed thereby |
CN1128049A (zh) | 1994-03-18 | 1996-07-31 | 犹他大学研究基金会 | 多肿瘤抑制因子基因种系突变及检测该基因癌肿倾向性的方法 |
US5631156A (en) * | 1994-06-21 | 1997-05-20 | The University Of Michigan | DNA encoding and 18 KD CDK6 inhibiting protein |
US6399296B1 (en) * | 1994-07-20 | 2002-06-04 | The General Hospital Corporation | Interaction trap systems for detecting protein interactions |
AU724324B2 (en) | 1995-07-17 | 2000-09-14 | Board Of Regents, The University Of Texas System | p16 expression constructs and their application in cancer therapy |
GB9519275D0 (en) | 1995-09-21 | 1995-11-22 | Univ Dundee | Substances and their therapeutic use |
US5669833A (en) * | 1996-08-21 | 1997-09-23 | Stone; David B. | Soccer training system |
-
1995
- 1995-09-21 GB GBGB9519275.3A patent/GB9519275D0/en active Pending
-
1996
- 1996-09-23 DE DE69605934T patent/DE69605934T2/de not_active Expired - Fee Related
- 1996-09-23 US US09/043,560 patent/US6569833B1/en not_active Expired - Fee Related
- 1996-09-23 JP JP51249897A patent/JP4077514B2/ja not_active Expired - Fee Related
- 1996-09-23 ES ES96931174T patent/ES2143780T3/es not_active Expired - Lifetime
- 1996-09-23 EP EP96931174A patent/EP0851922B1/en not_active Expired - Lifetime
- 1996-09-23 AT AT96931174T patent/ATE188254T1/de not_active IP Right Cessation
- 1996-09-23 WO PCT/GB1996/002340 patent/WO1997011174A1/en not_active Application Discontinuation
- 1996-09-23 AU AU69967/96A patent/AU6996796A/en not_active Abandoned
- 1996-09-23 KR KR1019980702005A patent/KR19990045761A/ko not_active Application Discontinuation
-
2002
- 2002-11-01 US US10/286,964 patent/US20040029791A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
KR19990045761A (ko) | 1999-06-25 |
ATE188254T1 (de) | 2000-01-15 |
DE69605934T2 (de) | 2000-06-15 |
AU6996796A (en) | 1997-04-09 |
JP2001507669A (ja) | 2001-06-12 |
GB9519275D0 (en) | 1995-11-22 |
US6569833B1 (en) | 2003-05-27 |
EP0851922A1 (en) | 1998-07-08 |
JP4077514B2 (ja) | 2008-04-16 |
US20040029791A1 (en) | 2004-02-12 |
DE69605934D1 (de) | 2000-02-03 |
EP0851922B1 (en) | 1999-12-29 |
WO1997011174A1 (en) | 1997-03-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2143780T3 (es) | Compuestos que enlazan las quinasas ciclinodependientes. | |
Huttner et al. | Differential phosphorylation of multiple sites in purified protein I by cyclic AMP-dependent and calcium-dependent protein kinases. | |
Goodenough et al. | Structural comparison of purified dynein proteins with in situ dynein arms | |
Saito et al. | Neurofilament-associated protein phosphatase 2A: its possible role in preserving neurofilaments in filamentous states | |
Cleveland et al. | Conservation of microtubule associated proteins. Isolation and characterization of tau and the high molecular weight microtubule associated protein from chicken brain and from mouse fibroblasts and comparison to the corresponding mammalian brain proteins | |
ATE397621T1 (de) | Hemmer der interaktion zwischen p53 und mdm2 | |
DE69533855D1 (de) | UNTERBRECHUNG DER BINDUNG DER PROTEINE MDM2 UND p53 UND ENTSPRECHENDE THERAPEUTISCHE ANWENDUNG | |
MX9606404A (es) | Composiciones farmaceuticas y metodos para formular trasnduccion de señales. | |
BRPI0407058A (pt) | Métodos de profilaxia e de tratamento de uma doença, composição farmacêutica, e, uso de um fragmento | |
Lindner et al. | The Microheterogeneity of the Mammalian H10Histone: EVIDENCE FOR AN AGE-DEPENDENT DEAMIDATION | |
Huang et al. | Purification and characterization of protein IIIb, a mammalian brain phosphoprotein. | |
BR9609424A (pt) | Novos peptìdeos, compostos, composição farmacêutica, processo para tratar um tumor em um mamìfero, e, processo para preparar os compostos | |
BR9910573A (pt) | Compostos antipicornavirais, preparação e uso dos mesmos | |
RU95111308A (ru) | Производные 2-амино-4-фенил-4-оксомасляной кислоты, способы получения, фармацевтическая композиция | |
BR0215395A (pt) | Compostos; processo para a preparação de um composto; composição farmacêutica; e método para o tratamento e/ou profilaxia de doenças que estão relacionadas com o nìvel de glicose no sangue | |
ATE107859T1 (de) | Verwendung von antiprogestomimetika zur stimulierung des eisprungs. | |
NO971966L (no) | Proteinkinase NPK-110 | |
ATE251886T1 (de) | Verwendunf von apoe zum binden von tau und map2c proteinen und zur behandlung von alzheimer's krankheit | |
DE69607034D1 (de) | Pcna bindende substanz | |
Keung et al. | Structure and function of ovotransferrin. I. Production of iron-binding fragments from iron-ovotransferrin by the action of immobilized subtilisin. Purification and characterization of the fragments. | |
Reisfeld et al. | Apolipoprotein B exhibits phospholipase A1 and phospholipase A2 activities | |
Marion et al. | Histone phosphorylation in native chromatin induces local structural changes as probed by electric birefringence | |
Spector et al. | The identification of O-phosphoserine in the soluble anionic phosphoproteins of bone | |
Juskevich et al. | Phosphorylation of brain cytosol proteins. Effects of phospholipids and calmodulin. | |
Seyedin et al. | H1 histones of trout. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG2A | Definitive protection |
Ref document number: 851922 Country of ref document: ES |